Head to head
Astrana Health vs HCA Healthcare
Side-by-side on the measures that matter, with a plain-English read. Full detail: ASTH · HCA
ASTH
Astrana Health
37.14+0.38%
1-year price shape — +22% over the period
Quant Rating C · 70/100
vs
HCA
HCA Healthcare
439.17+1.61%
1-year price shape — +1% over the period
Quant Rating D · 41/100
1-year performance, rebased to 100
HCA Healthcare edges it on the scoreable measures. HCA Healthcare trades cheapest on trailing earnings; HCA Healthcare pays the highest dividend yield; HCA Healthcare earns the most per share.
| ASTH | HCA | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 37.14 | 439.17 |
| Change today | +0.38% | +1.61% |
| 1-year return | +22.5% | +0.9% |
| Market cap | $2.07B | $95.08B |
| 52-week range | 18.08 – 51.60 | 353.34 – 553.56 |
| Valuation | ||
| P/E (TTM) | 45.29 | 14.73 |
| P/E percentile, own 5-yr range | 74th | 55th |
| P/B | 2.49 | -14.32 |
| Dividend yield | 0.00% | 0.68% |
| Profitability & growth | ||
| EPS (TTM) | 0.46 | 28.33 |
| Net profit (TTM) | $25.64M | $6.13B |
| Revenue (TTM) | $3.84B | $78.01B |
| Revenue growth (YoY) | +48.5% | +8.7% |
| Gross margin | 10.5% | 42.6% |
| Operating margin | 2.6% | 15.5% |
| Net margin | 1.1% | 8.8% |
| Free cash flow (TTM) | $94.38M | $6.00B |
| Ownership & sentiment | ||
| Institutional ownership | 76.7% | 94.6% |
| Insider activity (12mo) | 20 buy / 28 sell | 22 buy / 23 sell |
| Short interest (% of float) | 5.9% | 3.0% |
| Analyst consensus | 89% buy / 11% hold (9) | 64% buy / 32% hold / 5% sell (22) |
| Analyst price target | $52 (+40%) | $457 (+4%) |
| StockVane view | ||
| StockVane Quant Rating | C (70) | D (41) |
| Company | ||
| Employees | 3,000 | 320,000 |
| Founded | 1985 | 1968 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.